Bayesian semiparametric joint regression analysis of recurrent adverse events and survival in esophageal cancer patients

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We propose a Bayesian semiparametric joint regression model for a recurrent event process and survival time. Assuming independent latent subject frailties, we define marginal models for the recurrent event process intensity and survival distribution as functions of the subject’s frailty and baseline covariates. A robust Bayesian model, called Joint-DP, is obtained by assuming a Dirichlet process for the frailty distribution. We present a simulation study that compares posterior estimates under the Joint-DP model to a Bayesian joint model with lognormal frailties, a frequentist joint model, and marginal models for either the recurrent event process or survival time. The simulations show that the Joint-DP model does a good job of correcting for treatment assignment bias, and has favorable estimation reliability and accuracy compared with the alternative models. The Joint-DP model is applied to analyze an observational dataset from esophageal cancer patients treated with chemoradiation, including the times of recurrent effusions of fluid to the heart or lungs, survival time, prognostic covariates, and radiation therapy modality.

Original languageEnglish (US)
Pages (from-to)221-247
Number of pages27
JournalAnnals of Applied Statistics
Volume13
Issue number1
DOIs
StatePublished - 2019

Keywords

  • Accelerated failure time
  • Bayesian nonparametrics
  • Chemoradiation
  • Dirichlet process
  • Esophageal cancer
  • Joint model
  • Nonhomogeneous point process

ASJC Scopus subject areas

  • Statistics and Probability
  • Modeling and Simulation
  • Statistics, Probability and Uncertainty

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Bayesian semiparametric joint regression analysis of recurrent adverse events and survival in esophageal cancer patients'. Together they form a unique fingerprint.

Cite this